How much did Evotec achieve in EBIT for the current year?
In the current year, Evotec has achieved an EBIT of -78.6 M EUR.
Evotec EBIT 2024
Evotec EBIT
-78.6 M EUR
Ticker
EVT.DE
ISIN
DE0005664809
WKN
566480
In 2024, Evotec's EBIT was -78.6 M EUR, a 84.97% increase from the -42.5 M EUR EBIT recorded in the previous year.
The Evotec EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2029e | - |
| 2028e | 212.29 |
| 2027e | 170.42 |
| 2026e | 58.47 |
| 2025e | 2.12 |
| 2024e | -78.6 |
| 2023 | -42.5 |
| 2022 | 20.85 |
| 2021 | 41.68 |
| 2020 | 51.8 |
| 2019 | 74.51 |
| 2018 | 66.43 |
| 2017 | 37.91 |
| 2016 | 36.75 |
| 2015 | -2.53 |
| 2014 | 2.14 |
| 2013 | 4.1 |
| 2012 | 0.3 |
| 2011 | 5.8 |
| 2010 | 1.7 |
| 2009 | -19.6 |
| 2008 | -45.5 |
| 2007 | -49.2 |
| 2006 | -30.8 |
| 2005 | -16.9 |
| 2004 | -21.7 |
Evotec Revenue, EBIT, Net Income DE0005664809 · 566480
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Evotec, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Evotec from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Evotec’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Evotec. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Evotec’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Evotec’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Evotec’s growth potential.
Evotec Revenue, EBIT and net profit per share
| Date | Evotec Revenue | Evotec EBIT | Evotec Net Income |
|---|---|---|---|
| 2029e | 1.71 B undefined | 0 undefined | 97.54 M undefined |
| 2028e | 1.49 B undefined | 212.29 M undefined | 111.22 M undefined |
| 2027e | 1.34 B undefined | 170.42 M undefined | 84.85 M undefined |
| 2026e | 1.07 B undefined | 58.47 M undefined | 19.95 M undefined |
| 2025e | 926.84 M undefined | 2.12 M undefined | -25.97 M undefined |
| 2024e | 817.03 M undefined | -78.6 M undefined | -115.8 M undefined |
| 2023 | 781.43 M undefined | -42.5 M undefined | -83.91 M undefined |
| 2022 | 751.45 M undefined | 20.85 M undefined | -175.66 M undefined |
| 2021 | 618.03 M undefined | 41.68 M undefined | 215.51 M undefined |
| 2020 | 500.92 M undefined | 51.8 M undefined | 6.28 M undefined |
| 2019 | 446.44 M undefined | 74.51 M undefined | 38.07 M undefined |
| 2018 | 375.41 M undefined | 66.43 M undefined | 84.17 M undefined |
| 2017 | 263.77 M undefined | 37.91 M undefined | 23.48 M undefined |
| 2016 | 164.51 M undefined | 36.75 M undefined | 27.53 M undefined |
| 2015 | 127.68 M undefined | -2.53 M undefined | 16.52 M undefined |
| 2014 | 89.5 M undefined | 2.14 M undefined | -6.98 M undefined |
| 2013 | 85.9 M undefined | 4.1 M undefined | -25.4 M undefined |
| 2012 | 87.3 M undefined | 300,000 undefined | 2.5 M undefined |
| 2011 | 80.1 M undefined | 5.8 M undefined | 6.7 M undefined |
| 2010 | 55.3 M undefined | 1.7 M undefined | 3.3 M undefined |
| 2009 | 42.7 M undefined | -19.6 M undefined | -45.5 M undefined |
| 2008 | 39.6 M undefined | -45.5 M undefined | -78.3 M undefined |
| 2007 | 32.9 M undefined | -49.2 M undefined | -11.2 M undefined |
| 2006 | 67.4 M undefined | -30.8 M undefined | -32.5 M undefined |
| 2005 | 79.8 M undefined | -16.9 M undefined | -33.6 M undefined |
| 2004 | 72.7 M undefined | -21.7 M undefined | -84.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 72.7 M EUR | -21.7 M EUR | -84.2 M EUR |
| 2005 | 79.8 M EUR | -16.9 M EUR | -33.6 M EUR |
| 2006 | 67.4 M EUR | -30.8 M EUR | -32.5 M EUR |
| 2007 | 32.9 M EUR | -49.2 M EUR | -11.2 M EUR |
| 2008 | 39.6 M EUR | -45.5 M EUR | -78.3 M EUR |
| 2009 | 42.7 M EUR | -19.6 M EUR | -45.5 M EUR |
| 2010 | 55.3 M EUR | 1.7 M EUR | 3.3 M EUR |
| 2011 | 80.1 M EUR | 5.8 M EUR | 6.7 M EUR |
| 2012 | 87.3 M EUR | 300,000 EUR | 2.5 M EUR |
| 2013 | 85.9 M EUR | 4.1 M EUR | -25.4 M EUR |
| 2014 | 89.5 M EUR | 2.14 M EUR | -6.98 M EUR |
| 2015 | 127.68 M EUR | -2.53 M EUR | 16.52 M EUR |
| 2016 | 164.51 M EUR | 36.75 M EUR | 27.53 M EUR |
| 2017 | 263.77 M EUR | 37.91 M EUR | 23.48 M EUR |
| 2018 | 375.41 M EUR | 66.43 M EUR | 84.17 M EUR |
| 2019 | 446.44 M EUR | 74.51 M EUR | 38.07 M EUR |
| 2020 | 500.92 M EUR | 51.8 M EUR | 6.28 M EUR |
| 2021 | 618.03 M EUR | 41.68 M EUR | 215.51 M EUR |
| 2022 | 751.45 M EUR | 20.85 M EUR | -175.66 M EUR |
| 2023 | 781.43 M EUR | -42.5 M EUR | -83.91 M EUR |
| 2024e | 817.03 M EUR | -78.6 M EUR | -115.8 M EUR |
| 2025e | 926.84 M EUR | 2.12 M EUR | -25.97 M EUR |
| 2026e | 1.07 B EUR | 58.47 M EUR | 19.95 M EUR |
| 2027e | 1.34 B EUR | 170.42 M EUR | 84.85 M EUR |
| 2028e | 1.49 B EUR | 212.29 M EUR | 111.22 M EUR |
| 2029e | 1.71 B EUR | 0 EUR | 97.54 M EUR |
Evotec stock margins DE0005664809 · 566480
The Evotec margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evotec. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evotec.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Evotec's sales revenue. A higher gross margin percentage indicates that the Evotec retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Evotec's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Evotec's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Evotec's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Evotec. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Evotec's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Evotec Margin History
| Evotec Gross margin | Evotec Profit margin | Evotec EBIT margin | Evotec Profit margin |
|---|---|---|---|
| 2029e | 22.4 % | 0 % | 5.71 % |
| 2028e | 22.4 % | 14.24 % | 7.46 % |
| 2027e | 22.4 % | 12.7 % | 6.32 % |
| 2026e | 22.4 % | 5.47 % | 1.87 % |
| 2025e | 22.4 % | 0.23 % | -2.8 % |
| 2024e | 22.4 % | -9.62 % | -14.17 % |
| 2023 | 22.4 % | -5.44 % | -10.74 % |
| 2022 | 23.16 % | 2.77 % | -23.38 % |
| 2021 | 24.52 % | 6.74 % | 34.87 % |
| 2020 | 25.1 % | 10.34 % | 1.25 % |
| 2019 | 29.77 % | 16.69 % | 8.53 % |
| 2018 | 29.84 % | 17.69 % | 22.42 % |
| 2017 | 31.01 % | 14.37 % | 8.9 % |
| 2016 | 35.59 % | 22.34 % | 16.73 % |
| 2015 | 27.51 % | -1.98 % | 12.94 % |
| 2014 | 32.83 % | 2.39 % | -7.8 % |
| 2013 | 36.32 % | 4.77 % | -29.57 % |
| 2012 | 35.51 % | 0.34 % | 2.86 % |
| 2011 | 43.7 % | 7.24 % | 8.36 % |
| 2010 | 43.94 % | 3.07 % | 5.97 % |
| 2009 | 43.09 % | -45.9 % | -106.56 % |
| 2008 | 44.44 % | -114.9 % | -197.73 % |
| 2007 | 24.32 % | -149.54 % | -34.04 % |
| 2006 | 34.12 % | -45.7 % | -48.22 % |
| 2005 | 36.34 % | -21.18 % | -42.11 % |
| 2004 | 34.25 % | -29.85 % | -115.82 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 34.25 % | -29.85 % | -115.82 % |
| 2005 | 36.34 % | -21.18 % | -42.11 % |
| 2006 | 34.12 % | -45.7 % | -48.22 % |
| 2007 | 24.32 % | -149.54 % | -34.04 % |
| 2008 | 44.44 % | -114.9 % | -197.73 % |
| 2009 | 43.09 % | -45.9 % | -106.56 % |
| 2010 | 43.94 % | 3.07 % | 5.97 % |
| 2011 | 43.7 % | 7.24 % | 8.36 % |
| 2012 | 35.51 % | 0.34 % | 2.86 % |
| 2013 | 36.32 % | 4.77 % | -29.57 % |
| 2014 | 32.83 % | 2.39 % | -7.8 % |
| 2015 | 27.51 % | -1.98 % | 12.94 % |
| 2016 | 35.59 % | 22.34 % | 16.73 % |
| 2017 | 31.01 % | 14.37 % | 8.9 % |
| 2018 | 29.84 % | 17.69 % | 22.42 % |
| 2019 | 29.77 % | 16.69 % | 8.53 % |
| 2020 | 25.1 % | 10.34 % | 1.25 % |
| 2021 | 24.52 % | 6.74 % | 34.87 % |
| 2022 | 23.16 % | 2.77 % | -23.38 % |
| 2023 | 22.4 % | -5.44 % | -10.74 % |
| 2024e | 22.4 % | -9.62 % | -14.17 % |
| 2025e | 22.4 % | 0.23 % | -2.8 % |
| 2026e | 22.4 % | 5.47 % | 1.87 % |
| 2027e | 22.4 % | 12.7 % | 6.32 % |
| 2028e | 22.4 % | 14.24 % | 7.46 % |
| 2029e | 22.4 % | 0 % | 5.71 % |
Evotec Aktienanalyse
What does Evotec do?
Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Evotec's EBIT
Evotec's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Evotec's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Evotec's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Evotec’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Evotec stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Evotec.
How has the EBIT of Evotec developed in recent years?
The EBIT of Evotec has increased by 84.97% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Evotec?
The EBIT of Evotec is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Evotec pay?
Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.
What is the dividend yield of Evotec?
The current dividend yield of Evotec is .
When does Evotec pay dividends?
Evotec pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Evotec?
Evotec paid dividends every year for the past 0 years.
What is the dividend of Evotec?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Evotec located?
Evotec is assigned to the 'Health' sector.
Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Evotec from 11/8/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.
When did Evotec pay the last dividend?
The last dividend was paid out on 11/8/2024.
What was the dividend of Evotec in the year 2023?
In the year 2023, Evotec distributed 0 EUR as dividends.
In which currency does Evotec pay out the dividend?
The dividends of Evotec are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Andere Kennzahlen von Evotec
Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
